Impressive clinical data of anti-cancer drugs acts as a "catalyst"! Genmab (GMAB.US) market value soars by over $10 billion in a single week

According to Wise Finance APP, this week marked a breakthrough for Danish biotechnology company Genmab (GMAB.US). Two potential anti-cancer drugs reported positive late-stage clinical trial results, driving the company’s stock prices to record highs on both the Danish and US exchanges. Data shows that Genmab’s shares listed in Denmark rose 44% this week, marking the largest weekly gain since 2008, with its market capitalization increasing by more than 10 billion US dollars in a single week, and expanding its year-to-date gains to nearly 90%. At the same time, Genmab’s US-listed shares climbed 29% this week through Thursday’s close, hitting an all-time intraday high of 59.97 US dollars on Wednesday.